Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3 Open-Label Trial to Assess the Efficacy and Safety of KRN23 in Pediatric Patients With X-linked Hypophosphatemic Rickets/Osteomalacia and a Postmarketing Study of KRN23 Switched From the Phase 3 Trial

Next Previous
X
Search
Trial Profile

A Phase 3 Open-Label Trial to Assess the Efficacy and Safety of KRN23 in Pediatric Patients With X-linked Hypophosphatemic Rickets/Osteomalacia and a Postmarketing Study of KRN23 Switched From the Phase 3 Trial

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 07 Feb 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Burosumab (Primary)
  • Indications Osteomalacia; X-linked dominant hypophosphataemic rickets
  • Focus Adverse reactions
  • Sponsors Kyowa Kirin

    • Most Recent Events

    • 31 Jan 2023 Results from NCT03233126 and NCT04308096, assessing efficacy and safety of burosumab when administered either by a carer or patient , published in the Advances in Therapy
    • 31 Aug 2022 According to ClinicalTrials.gov record, protocol has been amended to change in primary endpoint timeframe from 88 weeks to 128 weeks.
    • 13 May 2020 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top